Drug | Effect on 5-HT Neuron Firing | Dose | Reference |
---|---|---|---|
In vitro studies | |||
(−)-Propranolol | ◂–▸3-a | 10 μM | Kidd et al., 1993 |
(±)-Tertatolol | ◂–▸ | 1 μM | Kidd et al., 1993 |
(−)-Tertatolol | ◂–▸ | 10 nM–10 μM | Jolas et al., 1993 |
WAY 100635 | ◂–▸ | 30 nM | Craven and Grahame-Smith, 1994 |
(+)-WAY 100135 | ◂–▸ | 10 nM–1 μM | Lanfumey et al., 1993 |
In vivo studies | |||
(−)-Alprenolol | ◂–▸ | >2 mg/kg i.v. | Millan et al., 1994 |
Spiperone | ◂–▸ | 1 mg/kg i.v. | Lum and Piercey, 1988; Blier et al., 1989b, 1993 |
S-UH-301 | ◂–▸⬆ | <0.25 mg/kg i.v. | Arborelius et al., 1995 |
(−)-Tertatolol | ◂–▸ | 0.5–4 mg/kg i.v. | Lejeune et al., 1993 |
(−)-Tertatolol | ◂–▸ | >2 mg/kg i.v. | Millan et al., 1994 |
(−)-Tertatolol | ◂–▸ | 0.1–0.5 mg/kg i.v. | Jolas et al., 1993 |
(−)-Tertatolol | ◂–▸ | 1 mg/kg i.v. | Prisco et al., 1993 |
(−)-Tertatolol | ◂–▸ | ID50> 4 mg/kg i.v. | Gobert et al., 1995 |
(+)-WAY 100135 | ◂–▸ | 0.1–1 mg/kg i.v. | Lejeune et al., 1993 |
(+)-WAY 100135 | ◂–▸ | 0.5 mg/kg i.v. | Piñeyro et al., 1996 |
(+)-WAY 100635 | ◂–▸⬆ | 0.1–0.5 mg/kg i.v. | Fornal et al., 1994 |
(+)-WAY 100135 | ◂–▸ | 1 mg/kg i.v. | Haddjeri and Blier, 1995 |
In vitro studies | |||
8-OH-DPAT | ⬇ | 3 nM–1 μM | Lanfumey et al., 1993 |
8-OH-DPAT | ⬇ | IC50, 10 nM | Jolas et al., 1993 |
8-OH-DPAT | ⬇ | IC50, 11 nM | Schechter et al., 1990 |
CM 57493 | ⬇ | 5–20 μM | Adrien et al., 1989 |
Ipsapirone | ⬇ | 50 nM | Jolas et al., 1993 |
Ipsapirone | ⬇ | 60 nM | Schechter et al., 1990 |
Lesopitron | ⬇ | 300 nM | Jolas et al., 1993 |
(+)-20499 | ⬇ | IC50, 6 nM | Kidd et al., 1993 |
(−)-S20500 | ⬇ | IC50, 130 nM | Schechter et al., 1990 |
BMY 7378 | ⬇ | 100–150 nM | Vandermaelen et al., 1987 |
BMY 7378 | ⬇ | IC50, 10 nM | Greuel and Glaser, 1991 |
NAN-190 | ⬇ | IC50, 20 nM | Greuel and Glaser, 1991 |
SDZ 216525 | ⬇ | 100 nM | Hamon et al., 1993 |
SDZ 216525 | ⬇ | 100 nM–1 μM | Lanfumey et al., 1990 |
(+)-WAY 100135 | ⬇ | 1 μM | Hamon et al., 1993 |
(+)-WAY 100135 | ⬇ | >1 μM | Lanfumey et al., 1993 |
In vivo studies | |||
BAY X 3702 | ⬇ | 0.45 μg/kg i.v. | Dong et al., 1998 |
8-OH-DPAT | ⬇ | 2 μg/kg i.v. | Blier and de Montigny, 1987; Blier et al., 1989b |
8-OH-DPAT | ⬇ | 1.5 μg/kg i.v. | Fornal et al., 1994a |
8-OH-DPAT | ⬇ | 1.5 μg/kg i.v. | Prisco et al., 1993 |
8-OH-DPAT | ⬇ | 2.2 μg/kg i.v. | Jolas et al., 1994 |
8-OH-DPAT | ⬇ | 0.6 μg/kg i.v. | Gobert et al., 1995 |
8-OH-DPAT | ⬇ | 1.6 μg/kg i.v. | McCall et al., 1994 |
8-OH-DPAT | ⬇ | 0.4 μg/kg i.v. | Arborelius et al., 1994 |
8-OH-DPAT | ⬇ | 1.5 μg/kg i.v. | Cox et al., 1990 |
5-MeOT | ⬇ | 45 μg/kg i.v. | Fornal et al., 1994a |
Buspirone | ⬇ | 75 μg/kg i.v. | Fornal et al., 1994a |
Buspirone | ⬇ | 15 μg/kg i.v. | McCall et al., 1994 |
CM 57493 | ⬇ | 5–20 mg/kg i.p. | Adrien et al., 1989 |
Flesinoxan | ⬇ | 108 μg/kg i.v. | Hadrava et al., 1995 |
Flesinoxan | ⬇ | 21 μg/kg i.v. | Gobert et al., 1995 |
Gepirone | ⬇ | 10 μg/kg i.v. | Blier and de Montigny, 1987 |
Ipsapirone | ⬇ | 83 μg/kg i.v. | Fornal et al., 1994 |
Ipsapirone | ⬇ | 7.5 μg/kg i.v. | Jolas et al., 1994 |
Ipsapirone | ⬇ | 3.7 μg/kg i.v. | Gobert et al., 1995 |
Ipsapirone | ⬇ | 30 μg/kg i.v. | Cox et al., 1990 |
Ipsapirone | ⬇ | 0.1–1 mg/kg i.p. | Adrien et al., 1993 |
LSD | ⬇ | 5 μg/kg i.v. | Blier et al., 1991; Godbout et al., 1991 |
LY 293284 | ⬇ | 0.08 μg/kg s.c. | Foreman et al., 1994 |
S 14671 | ⬇ | 0.16 μg/kg i.v. | Gobert et al., 1995 |
S 14506 | ⬇ | 0.3 μg/kg i.v. | Gobert et al., 1995 |
S 14671 | ⬇ | 0.16 μg/kg i.v. | Lejeune et al., 1993 |
S 14489 | ⬇ | 5 μg/kg i.v. | Millan et al., 1994 |
S 15535 | ⬇ | 7 μg/kg i.v. | Millan et al., 1994 |
S 15931 | ⬇ | 30 μg/kg i.p. | Millan et al., 1994 |
SR 57746A | ⬇ | 90–250 μg/kg i.v. | Bachy et al., 1993 |
Tandospirone | ⬇ | 3.4 μg/kg i.v. | Gobert et al., 1995 |
Tandospirone | ⬇ | 9.1 μg/kg i.v. | Godbout et al., 1991 |
U 92016A | ⬇ | 3.4 μg/kg i.v. | McCall et al., 1994 |
WY 48723 | ⬇ | 0.6 μg/kg i.v. | Gobert et al., 1995 |
Zalospirone | ⬇ | 3.6 μg/kg i.v. | McCall et al., 1994 |
BMY 7378 | ⬇ | 17.5 μg/kg i.v. | Cox et al., 1990 |
BMY 7378 | ⬇ | 1.5 μg/kg i.v. | Millan et al., 1994 |
BMY 7378 | ⬇ | 1.6 μg/kg i.v. | Gobert et al., 1995 |
BMY 7378 | ⬇ | 15.3 μg/kg i.v. | Fornal et al., 1994 |
MDL73005EF | ⬇ | 4 μg/kg i.v. | Millan et al., 1994 |
PAPP (LY165163) | ⬇ | 42 μg/kg i.v. | Sprouse and Aghajanian, 1987 |
Flibanserin | ⬇ | 239 μg/kg i.v. | Rueter et al., 1998 |
In vivo studies | |||
MDL 73005EF | ⬇ | 4.4 μg/kg i.v. | Gobert et al., 1995 |
NAN-190 | ⬇ | 4 μg/kg i.v. | Millan et al., 1994 |
NAN-190 | ⬇ | 3.9 μg/kg i.v. | Gobert et al., 1995 |
NAN-190 | ⬇ | 34.2 μg/kg i.v. | Fornal et al., 1994b |
SDZ 216525 | ⬇ | 0.1–0.5 mg/kg i.v. | Mundey et al., 1994 |
SDZ 216525 | ⬇ | 0.4 mg/kg i.v. | Fornal et al., 1994 |
SDZ 216525 | ⬇ | 47.3 μg/kg i.v. | Gobert et al., 1995 |
S-UH-301 | ⬇ | 0.5–4 mg/kg i.v. | Arborelius et al., 1994 |
(+)-WAY 100135 | ⬇ | 0.4 mg/kg i.v. | Fletcher et al., 1994 |
(+)-WAY 100135 | ⬇ | 0.25–0.50 mg/kg i.p. | Arborelius et al., 1995 |
(+)-WAY 100135 | ⬇ | 31 μg/kg i.v. | Escandon et al., 1994 |
(+)-WAY 100135 | ⬇ | 0.1–1 mg/kg i.v. | Fornal et al., 1994 |
Note: drugs have been ordered according to their efficacy in different systems. Because efficacy is system-dependent, drugs that figure as partial agonists in one experimental paradigm may appear as antagonists in another.
↵3-a ↔, no effect.